SCHEMBL2851189

SCHEMBL2851189

O=C/C(=C(/Cl)c1ccc(Cl)cc1)c1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.50
TSHR P16473 2/20 0.47
CASP1 P29466 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 2/20 0.44
HPGD P15428 2/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TCF4 P15884 1/20 0.44
CTNNB1 P35222 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPK1 P28482 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.42
PYGL P06737 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
FLT1 P17948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2851191 1.00 SRD5A2 (0.50) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL2846425 0.86 SRD5A2 (0.50) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL2846423 0.86 SRD5A2 (0.50) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL2845697 0.78 SRD5A2 (0.45) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL10996077 0.78 RAB9A (0.49) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL2845699 0.78 SRD5A2 (0.45) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL10996081 0.78 RAB9A (0.49) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL6160455 0.76 MAPT (0.50) SRD5A2TSHRCASP1SMN1; SMN2RAB9A
SCHEMBL1850553 0.74 TCF4 (0.66) SRD5A2TSHRSMN1; SMN2RAB9AHPGD
SCHEMBL1850554 0.74 TCF4 (0.66) SRD5A2TSHRSMN1; SMN2RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137402-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-06-03 US disclosed
US-7687537-B2 N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2010-03-30 US disclosed
US-20080009543-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2008-01-10 US disclosed
EP-1858872-A1 DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS Sanofi-Aventis (FR) 2007-11-28 EP disclosed
WO-2006084975-A1 DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS SANOFI-AVENTIS (FR) 2006-08-17 WO disclosed
EP-0132771-A2 1,2-Diaryl-3-azolylpropane derivatives, their preparation and use in plant treatment HOECHST AKTIENGESELLSCHAFT (DE) 1985-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009543-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CNR1, CNR2, GPR18 SRD5A2 2063/4885TSHR 323/4885CASP1 3719/4885
US-20100137402-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION CNR1, CNR2, GPR18 SRD5A2 2063/4885TSHR 323/4885CASP1 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.